Stocks · News reference
TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Tuesday, Exagen (NASDAQ:XGN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and
TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $10.
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.